The following is an excerpt of an article on bundled payments for joint replacement written by Michael Wong, JD, Executive Director of PPAHS and Lynn Razzano, RN, MSN, ONCC, Clinical Nurse Consultant at PPAHS. It was first appeared on The Doctor Weighs In on November 18, 2016. To read the full article, please click here.
The Physician-Patient Alliance for Health & Safety has been invited to become a partner of World Thrombosis Day, an international multi-organizational campaign devoted to increasing global awareness about thrombosis, including its causes, risk factors, signs/symptoms, evidence-based prevention and treatments.
World Thrombosis Day aims to highlight the need for action on thrombosis, specifically underscoring the unrecognized threat and serious consequences (morbidity and mortality) related to venous thromboembolism (VTE).
The guidelines for preventing VTE after total joint arthroplasty (such as, knee and hip replacement) by the Academy of Orthopaedic Surgeons and American College of Chest Physicians are unanimous – both pharmacological and mechanical prophylaxis are needed.
The AAOS recommends the use of pharmacological and/or mechanical compression devices for both total hip arthroplasty (THA) and total knee replacement (TKA) patients who are not at an elevated risk for VTE or bleeding, as well as for patients with a known bleeding disorder and/or active liver disease.
To better understand and develop practical solutions to prevent venous thromboembolism (VTE) in patients undergoing hip and knee replacement, PPAHS asks for you to complete this survey on patient safety in orthopedics.
PPAHS will be beginning a new #patientsafety campaign to develop practical solutions to help assess and prevent venous thromboembolism (VTE) in patients undergoing orthopedic procedures, particularly total knee and hip replacement. More commonly known as blood clots, VTE consists of both deep vein thrombosis (DVT) and pulmonary embolisms (PE) . Read More
By Michael Wong, JD (Executive Director, Physician-Patient Alliance for Health & Safety)
Editor’s Note: This is the first post in what we hope will become a regular series of opinion pieces which ask our readers to comment on what could be considered controversial. Maternal patients are at risk for venous thromboembolism (VTE, commonly referred to as blood clots), which has been identified as a patient safety issue. In this post, the question asked is whether the recent deaths of young women due to blood clots from taking birth control pills is also a patient safety issue.
Being pregnant increases the risks of blood clots. “For pregnant women, the risk of VTE is 4-5 times higher than women who are not pregnant,” says Andra James, MD (Professor of Obstetrics & Gynecology, Division of Maternal Fetal Medicine, University of Virginia School of Medicine). “Moreover, this risk is at least twice as much following cesarean delivery.”
Two patient deaths – one from alarm fatigue and one from a blood clot – make us stop and ask, “Are we doing enough to prevent patient deaths?
Death from Blood Clots
A teenage mother-to-be and her unborn baby were tragically killed by a DVT blood clot – just hours after finding out she was expecting a healthy boy.
Scarlett Holyoake, 18, was six months pregnant when she suddenly died from deep vein thrombosis after collapsing in her home.
In a recent article, Peter Pronovost, MD, PhD, FCCM (Professor, Departments of Anesthesiology/Critical Care Medicine and Surgery, The Johns Hopkins University School of Medicine and Medical Director, Center for Innovation in Quality Patient; Member of the Physician-Patient Alliance for Health & Safety PCA Safety Panel and OB VTE Recommendations Working Group) asks a great question, “Patient Safety at 15: How Much Have We Grown?”.
Dr. Pronovost reflects on the past 15 years: